Anti-CD3/anti-TRBC1 bispecific T-cell engager (Meiji Seika Pharma)

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameAnti-CD3/anti-TRBC1 bispecific T-cell engager (Meiji Seika Pharma)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionCD3 T-cell engagersAnti-TRBC1

TargetsT cell surface glycoprotein CD3TRBC1

Therapy Area/IndicationsLymphoma, T-CellLeukemia, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryJapan

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMeiji Seika Pharmatech Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesMeiji Seika Pharmatech Co Ltd

Inactive CompaniesN/A

Active IndicationsLymphoma, T-CellLeukemia, T-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A